Lamivir 150 Tablet

Lamivir 150 Tablet – Lamivudine (150mg)

Lamivir 150 Tablet contains Lamivudine 150mg, a nucleoside reverse transcriptase inhibitor (NRTI) manufactured by Cipla Ltd. It is used as part of combination antiretroviral therapy for HIV-1 infection, working by blocking an enzyme the virus needs to multiply.

Key Features

• Single-agent NRTI antiretroviral tablet, made by Cipla
• Contains Lamivudine 150mg
• Used as part of combination ART regimens for HIV-1
• Also used in chronic Hepatitis B management at appropriate doses
• Strip of 10 tablets, Schedule H prescription drug

Composition

• Lamivudine (150mg)

Uses & Benefits

• Used in combination with other antiretrovirals to treat HIV-1 infection
• Helps reduce HIV viral load as part of a broader ART regimen
• Supports immune system recovery over time
• Used under physician supervision as part of a structured treatment plan

Directions for Use

• Take exactly as prescribed by your physician, alongside other prescribed antiretrovirals
• Usually taken with or without food, at the same times each day
• Swallow the tablet whole with water
• Do not skip doses to help prevent drug resistance

Precautions

• Use only under the supervision of a qualified physician
• Inform your doctor of any kidney or liver conditions before starting treatment
• Regular monitoring of blood counts, liver and kidney function may be required
• Inform your healthcare provider about all other medications you are taking
• Consult your doctor before use during pregnancy or breastfeeding
• Do not skip or stop doses without medical advice, as this may lead to drug resistance

Storage

• Store below 30°C in a cool, dry place
• Keep out of reach of children
• Protect from excessive heat and moisture

Disclaimer

This is a Schedule H prescription medicine. This information is for general awareness and is not a substitute for professional medical advice, diagnosis or treatment. Do not start, stop or change the dose without consulting a qualified healthcare provider.